CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products

163Citations
Citations of this article
290Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed the treatment landscape of B-cell non-Hodgkin’s lymphoma (NHL), especially for aggressive B-cell lymphomas. Single-center and multicenter clinical trials with anti-CD19 CAR T-cell therapy have shown great activity and long-term remissions in poor-risk diffuse large B-cell lymphoma (DLBCL) when no other effective treatment options are available. Two CAR T-cell products [axicabtagene ciloleucel (axi-cel) and tisagenlecleucel] have obtained US Food and Drug Administration approval for the treatment of refractory DLBCL after two lines of therapy. A third product, liso-cel, is currently being evaluated in clinical trials and preliminary results appear very promising. CAR T-cell-related toxicity with cytokine-release syndrome and neurotoxicity remain important potential complications of this therapy. Here, we review the s biology, structure, clinical trial results and toxicity of two commercially approved CAR T-cell products and others currently being studied in multicenter clinical trials in B-cell NHLs.

Cite

CITATION STYLE

APA

Chavez, J. C., Bachmeier, C., & Kharfan-Dabaja, M. A. (2019). CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Therapeutic Advances in Hematology. SAGE Publications Ltd. https://doi.org/10.1177/2040620719841581

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free